16-Dehydro-pregnenolon

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 16-Dehydro-pregnenolon
• 英文别名: 5,16-Pregnadien-3beta-ol-20-one；1-[(3S,10R,13S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
• 化学式: C₂₁H₃₀O₂
• 分子量: 314.468
• InChiKey: YLFRRPUBVUAHSR-IQJXLZMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  16-Dehydro-pregnenolon 在 硫酸 、 aluminum isopropoxide 作用下， 以 水 、 环己酮 、 甲苯 为溶剂， 以90.6 %的产率得到16-Dehydro-progesteron
  参考文献：
  名称：

  CN117264005

  摘要：

  公开号：
• 作为产物：
  描述：

  3β-acetoxy-pregna-5,16-dien-20-one 在 甲基三辛基氯化铵 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 5.5h， 以99%的产率得到16-Dehydro-pregnenolon
  参考文献：
  名称：

  水不溶性高熔点有机底物水反应的实用解决方案

  摘要：

  对于难溶性高熔点（VSSHMP）有机底物进行水反应的问题，已经开发出一种实用的解决方案，该方法需要机械搅拌底物，相应的试剂，水，催化性Aliquat 336的混合物和沙子。当包括类固醇，酮，醛，芳族化合物和生物碱的底物的熔点为约200℃时，反应可以在20℃下进行。底物溶解度可以低至1×10 -10 mol L -1。

  DOI：

  10.1039/c2gc16328d

文献信息

• Ceric ammonium nitrate (CAN)—a useful catalyst for the rapid and high-yield esterification of carboxylic acids and alcohols with special reference to steroid and other multi-functional natural products
  作者：Papori Goswami、Pritish Chowdhury

  DOI：10.1039/b005908k

  日期：——

  Ceric ammonium nitrate (CAN) acts as a versatile catalyst for the esterification of carboxylic acids and alcohols, including steroids and other multi-functional natural products, in excellent yields under mild and convenient reaction conditions.

  硝酸铈铵（CAN）用作通用的催化剂，可在温和便捷的反应条件下以优异的收率将羧酸和醇类（包括类固醇和其他多功能天然产物）酯化。
• Antagonists of CB1 receptor
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US10040816B2

  公开（公告）日：2018-08-07

  The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.

  本发明涉及一种 CB1 受体拮抗剂，用于治疗选自以下组别的病理状况或紊乱：膀胱和胃肠道疾病；炎症性疾病；心血管疾病；肾病；青光眼；痉挛；癌症；骨质疏松症；代谢紊乱；肥胖；成瘾、依赖、滥用和复发相关紊乱；精神和神经紊乱；神经退行性疾病；自身免疫性肝炎；骨质疏松症；代谢紊乱；肥胖；成瘾、依赖、滥用和复发相关疾病；精神和神经系统疾病；神经退行性疾病；自身免疫性肝炎和脑炎；疼痛；生殖系统疾病以及皮肤炎症和纤维化疾病。
• Goswami, Papori; Hazarika, Saroj; Borah, Parinita, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2003, vol. 42, # 3, p. 678 - 682
  作者：Goswami, Papori、Hazarika, Saroj、Borah, Parinita、Chowdhury, Pritish

  DOI：——

  日期：——
• MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION
  申请人：Ferguson Mark W. J.

  公开号：US20100144690A1

  公开（公告）日：2010-06-10

  Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm 2 of a wound or fibrotic disorder, over a 24 hour period in order to inhibit scarring.
• Antagonists of CB1 Receptor
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US20160145294A1

  公开（公告）日：2016-05-26

  The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.